80072198 - 22nd Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases

Friday, September 25, 2026, 7:00 AM - Saturday, September 26, 2026, 5:00 PM, Johns Hopkins Asthma and Allergy Center, Baltimore, MD

Now in its 22nd year, this two day symposium is designed for healthcare professionals involved in the care of patients with rheumatic diseases. As the spectrum of rheumatologic conditions continues to expand, alongside rapid advancements in diagnostic technologies and therapeutic options clinicians must stay current with evolving best practices. This activity will provide participants with evidence based strategies for early diagnosis, highlight state of the art diagnostic tools, and review the most effective, patient centered treatment approaches to optimize outcomes. New this year, the symposium features an in-person musculoskeletal ultrasound workshop led by nationally recognized experts, offering hands on learning to enhance practical ultrasonographic skills. We are also convening an “Expert Panel Discussion” where the symposium participants will discuss their difficult – to – treat and challenging cases with the panel.

1. Recognize the clinical manifestations of VEXAS syndrome and apply appropriate treatment strategies.
2. Evaluate emerging pharmacologic therapies for the management of fibromyalgia.
3. Differentiate current guideline based approaches for the treatment of nonrenal systemic lupus erythematosus (SLE).
4. Assess novel therapeutic options for the management of Sjgrens disease.

COURTYARD by Marriott Downtown Inner Harbor

1000 Aliceanna Street, Baltimore, MD 21202

443-923-4000

Room Rate: $159.00

Reservation Link:

www.marriott.com

Cut off Date: August 24, 2026

Mitigation of Relevant Financial Relationships

Johns Hopkins University adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.